Format

Send to

Choose Destination
Clin Liver Dis. 2012 May;16(2):397-419. doi: 10.1016/j.cld.2012.03.005.

Nonalcoholic fatty liver disease.

Author information

1
Division of Gastroenterology, Department of Medicine, Walter Reed National Military Medical Center, Bethesda, MD 20889, USA.

Abstract

As the hepatic manifestation of the metabolic syndrome, nonalcoholic fatty liver disease (NAFLD) has become the most common cause of asymptomatic liver enzyme elevations in Western nations. Although it is easy to diagnose NAFLD, a liver biopsy is currently required to diagnose nonalcoholic steatohepatitis (NASH). Patients with NASH are those at greatest risk of progression to cirrhosis and, thus, treatment efforts are targeted to these individuals. Although currently there are no FDA-approved treatments for NASH, a multidisciplinary approach that addresses comorbid conditions and promotes modest weight loss comprises the backbone of therapy.

PMID:
22541706
DOI:
10.1016/j.cld.2012.03.005
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center